Regulatory

Latest News

drug prices rising | Image credit: arhendrix - stock.adobe.com
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High

May 17th 2025

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.

Cimerli is indicated for nAMD | Image credit: Dilshad | stock.adobe.com
Cimerli Offers a New, Interchangeable Biosimilar for Ocular Conditions

May 15th 2025

laboratory for biosimilar development | Image credit: 201606422 - stock.adobe.com
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships

April 29th 2025

eye on pharma banner
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick

April 22nd 2025

laboratory | image credit: Cavan -stock.adobe.com
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars

April 21st 2025

Video Interviews
Podcasts
CFB podcast banner
CFB podcast banner
CFB podcast banner
CFB podcast banner
CfB Podcast Banner
"SEEING EYE TO EYE:  Exploring Different Perspectives on Ophthalmology Biosimilars SEEING EYE TO EYE:  Exploring Different Perspectives on Ophthalmology Biosimilars" with the CfB logo and an image of an eye
CfB podcast banner
CfB podcast banner
podcast banner
image of adalimumab biosmilar eveloped by alvotech prefilled syring

More News

© 2025 MJH Life Sciences

All rights reserved.